Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01545635
Other study ID # RETIC
Secondary ID
Status Terminated
Phase Phase 3
First received March 1, 2012
Last updated March 22, 2016
Start date March 2012
Est. completion date February 2016

Study information

Verified date March 2016
Source Medical University Innsbruck
Contact n/a
Is FDA regulated No
Health authority Austria: Federal Office for Safety in Health Care
Study type Interventional

Clinical Trial Summary

Severe traumatized patients (ISS > 15) admitted to emergency department (ED) University Hospital Innsbruck with obvious bleeding and/or who are at risk for significant hemorrhage will be screened by rotational thrombelastometry (ROTEM) assays during ED treatment and subsequent surgical/radiological interventions for having coagulopathy (T0). If a patient meets the inclusion criteria (T1) and is recruited for the study, a first study related blood sample (40mL) will be drawn, and data collected. Subsequently, 100 patients will be randomized to receive Fibrinogen concentrate and/or Prothrombin complex concentrate and/or FXIII concentrate for reversal of coagulopathy, while the other 100 patients will receive fresh frozen plasma (FFP),respectively.

Treatment failure will be registered if bleeding persists and ROTEM parameters do not improve after two times dosages of study drug. In these cases haemostatic rescue therapy will be administered. CFC (fibrinogen concentrate and/or PCC, and/or FXIII concentrate) will be administered to patients randomized to receive FFP and FFP will be administered to patients of the CFC group.

In cases unresponsive to comprehensive treatment or normal ROTEM combined with diffuse bleeding, other haemostatic medications can be administered (e.g rFVIIa, DDAVP, VWF/FVIII concentrate) as judged by the anesthetist in charge. The need and type of any rescue therapy will be documented and a ROTEM will be performed thereafter.

At admission to ICU (T0 ICU), 24h (T24 ICU) and 48h(T48 ICU) thereafter further study related blood samples are drawn (40mL each).

The indications for transfusion of red blood cells or platelets, administration of antifibrinolytics, treatment of acidosis, hypothermia, hypocalcemia and volume replacement are similar for both groups and treatment is performed according to clinical routine.

Besides coagulation management during ED treatment until 24h on ICU, patient's care is not influenced by the study and follows clinical routine.


Recruitment information / eligibility

Status Terminated
Enrollment 100
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Male and female subjects =/> 18 years and =/< 80 years

2. Major trauma (ISS > 15)

3. Clinical signs of ongoing bleeding or patients who are at risk for significant haemorrhage assessed and judged by the ED team in charge of patient

4. Presence of coagulopathy defined by ROTEM assays as follows,

- Patients with concomitant decreased fibrinogen polymerisation (ROTEMĀ® FibTEM A10 of < 7 mm after 10 min)

- Patients with concomitant decreased coagulation factor levels (ROTEMĀ® ExTEM CT of > 90 sec)

Exclusion Criteria:

1. Lethal injury

2. CPR on the scene,

3. Isolated brain injury, burn injury

4. Avalanche injury

5. Administration of FFP or coagulation factor concentrates before ED admission

6. Delayed (> 6hours after trauma) admittance to ED

7. Known use of oral anticoagulants, or platelet aggregation inhibitors within 5 days before injury

8. Known history of severe allergic reaction to plasma products

9. Known history of congenital hemostasis disturbance, IgA or Protein C deficiency

10. Patients with a history of thromboembolic events or heparin induced thrombocytopenia (HIT) type 2 within the last year

11. Patients with a body weight < 45kg and > 150kg

12. Patients that are known to be pregnant

13. Jehova's Witness

14. Known participation in another clinical trial

15. Patient with known refusal of a participation in this clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate
Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
Fresh Frozen Plasma blood type 0, A, B and AB
Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min

Locations

Country Name City State
Austria Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine Innsbruck Tyrol

Sponsors (1)

Lead Sponsor Collaborator
Medical University Innsbruck

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multiple Organ Failure (MOF) Difference in the MOF as assessed by the Sequential Organ Failure Assessment score (SOFA) between treatment groups. Variable until 24h on ICU at the end of the IMP-administration No
See also
  Status Clinical Trial Phase
Recruiting NCT02509390 - Hyperfibrinogenemia After Major Trauma N/A
Recruiting NCT04970433 - The Effects of Acupuncture for Major Trauma N/A
Recruiting NCT04588311 - ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Phase 3
Active, not recruiting NCT04144803 - Brain Oxygenation During Prehospital Anesthesia: an Observational Study
Completed NCT03259776 - Experiences of Visitors to a Regional Major Trauma Intensive Care Unit
Recruiting NCT05449522 - Vitamin D for Critically Traumatic Patients N/A
Not yet recruiting NCT06103292 - Calcium Levels in Major Trauma
Recruiting NCT02877342 - Pre-hospital Notification of Injured Patients Presenting to Trauma Centres in India N/A
Completed NCT03986736 - Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma
Completed NCT03005509 - Structured Trauma Quality Improvement Meetings at Four Trauma Centres in India N/A
Completed NCT02165137 - Management of Major Trauma Patients at Aarau Trauma Center - Evaluation of Processes and Patient Outcome
Active, not recruiting NCT06376318 - Shock and Acute Conditions OutcOmes Platform
Recruiting NCT05996068 - Arterial Line in Trauma Resuscitation N/A
Completed NCT06007807 - Severe Trauma Registry in Tarragona
Completed NCT03354559 - Trauma Associated Bleeding: Effectiveness of an Early Coagulation Support Protocol N/A
Recruiting NCT05652790 - Enhanced Rehabilitation After Major Trauma (PROPERLY) N/A
Completed NCT00588796 - Study of Fibrinogen Metabolism During Severe Trauma and Burns N/A
Completed NCT04216459 - Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis N/A
Terminated NCT04551157 - Impact of Psychoeducational Video on Adjustment to Open Fracture. N/A
Completed NCT02000674 - Succinylcholine vs Rocuronium for Prehospital Emergency Intubation Phase 3